- RNA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $16.5 million.
- RNA has traded 65,615 shares today.
- RNA is down 6.4% today.
- RNA was up 8.6% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in RNA with the Ticky from Trade-Ideas. See the FREE profile for RNA NOW at Trade-Ideas More details on RNA: Prosensa Holding N.V., a biotechnology company, engages in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders. Currently there are 3 analysts that rate Prosensa a buy, no analysts rate it a sell, and 1 rates it a hold. The average volume for Prosensa has been 315,900 shares per day over the past 30 days. Prosensa has a market cap of $671.6 million and is part of the health care sector and drugs industry. Shares are up 300.4% year-to-date as of the close of trading on Tuesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Prosensa as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.